118 related articles for article (PubMed ID: 36800641)
1. Guanidinium-Rich Lipopeptide-Based Nanoparticle Enables Efficient Gene Editing in Skeletal Muscles.
Zhu M; Wang X; Xie R; Wang Y; Xu X; Burger J; Gong S
ACS Appl Mater Interfaces; 2023 Mar; 15(8):10464-10476. PubMed ID: 36800641
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
[TBL] [Abstract][Full Text] [Related]
3. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice.
Kenjo E; Hozumi H; Makita Y; Iwabuchi KA; Fujimoto N; Matsumoto S; Kimura M; Amano Y; Ifuku M; Naoe Y; Inukai N; Hotta A
Nat Commun; 2021 Dec; 12(1):7101. PubMed ID: 34880218
[TBL] [Abstract][Full Text] [Related]
4. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH
J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491
[TBL] [Abstract][Full Text] [Related]
5. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
[TBL] [Abstract][Full Text] [Related]
6. A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries.
Wang Y; Shahi PK; Xie R; Zhang H; Abdeen AA; Yodsanit N; Ma Z; Saha K; Pattnaik BR; Gong S
J Control Release; 2020 Aug; 324():194-203. PubMed ID: 32380204
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanoparticle-based ribonucleoprotein delivery for in vivo genome editing.
Onuma H; Sato Y; Harashima H
J Control Release; 2023 Mar; 355():406-416. PubMed ID: 36773957
[TBL] [Abstract][Full Text] [Related]
8. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
9. Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 RNP.
Chen K; Han H; Zhao S; Xu B; Yin B; Trinidad M; Burgstone BW; Murthy N; Doudna JA
bioRxiv; 2023 Nov; ():. PubMed ID: 38014175
[TBL] [Abstract][Full Text] [Related]
10. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy.
Wan T; Chen Y; Pan Q; Xu X; Kang Y; Gao X; Huang F; Wu C; Ping Y
J Control Release; 2020 Jun; 322():236-247. PubMed ID: 32169537
[TBL] [Abstract][Full Text] [Related]
11. Versatile Redox-Responsive Polyplexes for the Delivery of Plasmid DNA, Messenger RNA, and CRISPR-Cas9 Genome-Editing Machinery.
Wang Y; Ma B; Abdeen AA; Chen G; Xie R; Saha K; Gong S
ACS Appl Mater Interfaces; 2018 Sep; 10(38):31915-31927. PubMed ID: 30222305
[TBL] [Abstract][Full Text] [Related]
12. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
[TBL] [Abstract][Full Text] [Related]
13. Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.
Bykonya AG; Lavrov AV; Smirnikhina SA
Mol Biotechnol; 2023 Feb; 65(2):181-195. PubMed ID: 35322386
[TBL] [Abstract][Full Text] [Related]
14. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
15. Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy.
Ruan W; Jiao M; Xu S; Ismail M; Xie X; An Y; Guo H; Qian R; Shi B; Zheng M
J Control Release; 2022 Nov; 351():739-751. PubMed ID: 36174804
[TBL] [Abstract][Full Text] [Related]
16. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
17. Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient 'hit-and-run' genome editing.
Lyu P; Javidi-Parsijani P; Atala A; Lu B
Nucleic Acids Res; 2019 Sep; 47(17):e99. PubMed ID: 31299082
[TBL] [Abstract][Full Text] [Related]
18. In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles.
Wang Y; Shahi PK; Wang X; Xie R; Zhao Y; Wu M; Roge S; Pattnaik BR; Gong S
J Control Release; 2021 Aug; 336():296-309. PubMed ID: 34174352
[TBL] [Abstract][Full Text] [Related]
19. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
Li S; Song Z; Liu C; Chen XL; Han H
ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
[TBL] [Abstract][Full Text] [Related]
20. Genome Editing in a Wide Area of the Brain Using Dendrimer-Based Ternary Polyplexes of Cas9 Ribonucleoprotein.
Taharabaru T; Yokoyama R; Higashi T; Mohammed AFA; Inoue M; Maeda Y; Niidome T; Onodera R; Motoyama K
ACS Appl Mater Interfaces; 2020 May; 12(19):21386-21397. PubMed ID: 32315156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
